Peptides DB
Research-centric peptide and protocol reference hub

Lanreotide record · updated 10h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 17 studiesJump to the evidenceCompare
What is Lanreotide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: SSTR2 agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Lanreotide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 100 registered trials. It describes the research record, not a recommendation.

Identity
NameLanreotide
Chain length—
Molecular weight1,096.3 Da
FormulaC54H69N11O10S2
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 6918011. No verified residue count for this compound.

Pharmacology
MechanismSSTR2 agonist
RouteSubcutaneous injection
Half-life~30 min
Time to peak1–2 hours
Durationup to 28 days
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 22, 2026. How this works →
Research stats
Total studies17
Human / animal / cellular13 / 2 / 0
Highest trial phasePhase 3
Years covered2023–2026
Latest study2d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reports6,484
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

17 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
When Thyrotropin Meets Growth Hormone: Clinical Challenges of a Mixed GH/TSH-Secreting PIT1-Lineage Pituitary Neuroendocrine Tumor
FindingIGF-1 decreased from 1128 ng/mL to 846 ng/mL after lanreotide treatment.
Human2026Full text read0.80
Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.
FindingSCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference -3.73% (95% CI -6.93, -0.55; p = .0317)
Human2026Full text read0.80
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
FindingCohort 1 maintained an MBE of 74.7% body weight reduction with orforglipron vs 49.2% with placebo at week 52, P<0.001.
Human2026Full text read0.80
Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm
FindingSerum CgA reduced from 3636 to <100 ng/mL after five months.
Human2023Full text read0.80
Patient Point of View of the diagnosis, treatment and follow up in acromegaly: Single center study from a tertiary center
FindingOverall disease control achieved in 38 patients (65.5%).
Human2024Full text read0.80
Heterozygous Men1+/T knockout mice do not develop bronchopulmonary neuroendocrine hyperplasia or neoplasia but bronchial adenocarcinoma
FindingNo bronchopulmonary neuroendocrine cell hyperplasia or neoplasia detected in 30 mice evaluated.
Animal2024Full text read0.80
<p class="MDPI12title"><span lang="EN-US" style="mso-bidi-font-size: 18.0pt;">In vivo and In Vitro Efficacy of Statin Therapy in Combination with Somatostatin Analogues in Advanced Bronchopulmonary Neuroendocrine Tumors
FindingNot reported in abstract.
Human2026Full text read0.70
Comparative predictive performance of three machine learning algorithms for acute radiation enteritis risk among patients with cervical cancer undergoing radiotherapy: A prospective cohort study.
FindingRandom Forest model AUC was 0.961.
Human2026Full text read0.80
Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.
FindingPreterm birth occurred in 18.2% and 19.7% of participants in the vaccine and placebo groups, respectively.
Human2026Full text read0.80
The adiponectin/leptin ratio as a biomarker of adiposopathy and visceral adipose tissue accumulation: sex-specific mechanisms.
FindingALR inversely associated with VAT area in postmenopausal females, p<0.05.
Human2026Full text read0.80
Association of dietary habits and physical activity with the severity of fecal incontinence in patients with colorectal cancer after minimally invasive surgery: An exploratory study.
Findingβ = -1.42; 95% CI, -2.71 to -0.12 for red meat intake.
Human2026Full text read0.80
Maternal diet shapes neonatal microbiome ontogenesis and neurometabolic resilience.
FindingNot reported in abstract.
Animal2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Lanreotide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Lanreotide is discussed should be drawn from it.